{"transactions":[{"id":2629105,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-20T16:17:27.000Z","date":"2021-07-14","kind":"sale","acquired":false,"shares":917,"price":34.0076,"value":31184.9692,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein."}],"balance_after":38708,"source":{"system":"sec-edgar","filing":"0000899243-21-028984","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000089924321028984/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-15"}},{"id":2629104,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-20T16:17:27.000Z","date":"2021-07-13","kind":"sale","acquired":false,"shares":12,"price":33.5,"value":402.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein."}],"balance_after":39625,"source":{"system":"sec-edgar","filing":"0000899243-21-028984","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000089924321028984/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-15"}},{"id":2629103,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-20T16:17:27.000Z","date":"2021-07-14","kind":"sale","acquired":false,"shares":43378,"price":34.0076,"value":1475181.6728,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein."}],"balance_after":1831671,"source":{"system":"sec-edgar","filing":"0000899243-21-028984","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000089924321028984/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-15"}},{"id":2629102,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-20T16:17:27.000Z","date":"2021-07-13","kind":"sale","acquired":false,"shares":588,"price":33.5,"value":19698.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein."}],"balance_after":1875049,"source":{"system":"sec-edgar","filing":"0000899243-21-028984","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000089924321028984/doc4a.xml","form_type":"4/A","original_submission_date":"2021-07-15"}},{"id":2633065,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-15T19:03:02.000Z","date":"2021-07-14","kind":"sale","acquired":false,"shares":917,"price":34.0076,"value":31184.9692,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein."}],"balance_after":38708,"source":{"system":"sec-edgar","filing":"0000899243-21-028546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000089924321028546/doc4.xml","form_type":"4"}},{"id":2633064,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-15T19:03:02.000Z","date":"2021-07-13","kind":"sale","acquired":false,"shares":12,"price":33.5,"value":402.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein."}],"balance_after":39625,"source":{"system":"sec-edgar","filing":"0000899243-21-028546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000089924321028546/doc4.xml","form_type":"4"}},{"id":2633063,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-15T19:03:02.000Z","date":"2021-07-14","kind":"sale","acquired":false,"shares":43378,"price":34.0076,"value":1475181.6728,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein."}],"balance_after":1831671,"source":{"system":"sec-edgar","filing":"0000899243-21-028546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000089924321028546/doc4.xml","form_type":"4"}},{"id":2633062,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-15T19:03:02.000Z","date":"2021-07-13","kind":"sale","acquired":false,"shares":588,"price":33.5,"value":19698.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein."}],"balance_after":1875049,"source":{"system":"sec-edgar","filing":"0000899243-21-028546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000089924321028546/doc4.xml","form_type":"4"}},{"id":2919751,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-05T17:25:18.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19000,"derivative":{"exercise_price":17.95,"exercise_date":"2021-01-04","expiration_date":"2031-01-04","underlying":"Ordinary Shares","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-21-001321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000120919121001321/doc4.xml","form_type":"4"}},{"id":3317913,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-06T16:51:49.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":9.82,"exercise_date":"2020-01-02","expiration_date":"2030-01-02","underlying":"Ordinary Shares","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-20-001917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000120919120001917/doc4.xml","form_type":"4"}},{"id":3507316,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B1 Preferred Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":13169,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":13169},"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507315,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":18485,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18485},"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507314,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B1 Preferred Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":623196,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":623196},"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507313,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":874709,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":874709},"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507312,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":7983,"price":14,"value":111762.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":39637,"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507311,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":377732,"price":14,"value":5288248.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1875637,"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507310,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":13169,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":31654,"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507309,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":18485,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":18485,"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507308,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":623196,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1497905,"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}},{"id":3507307,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":137195,"kind":"person","name":"BINGHAM KATE","position":1,"cik":"0001185040","reported_name":"BINGHAM KATE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:10.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":874709,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":874709,"source":{"system":"sec-edgar","filing":"0001104659-19-032915","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1185040/000110465919032915/a4.xml","form_type":"4"}}]}